South Africa's Competition Commission is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday, 4 ...

The race between Novo Nordisk A/S (ADR) (NYSE:NVO) and Sanofi SA (ADR) (NYSE:SNY) combination diabetes therapies is now down to the wire, with Novo pulling ahead after a delay was slapped on Sanofi.

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the ...